Evidence map›Paper›PMID 32329653›Full record

ArticleCell cycle (Georgetown, Tex.)2020

Microvesicles derived from human umbilical cord mesenchymal stem cells ameliorate renal ischemia-reperfusion injury via delivery of miR-21.

Tao Du, Jun Zhou, Wen-Xia Chen, Xiao-Li Zhang, Tong-Yu Ji, Jie Liu, Lu Rong, Ling-Dian Wang, Rui-Jin Zhou, De-Gang Ding

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Tao DuDepartment of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital , Zhengzhou, Henan, China.
Jun ZhouDepartment of Urology, Henan University People's Hospital; Henan Provincial People's Hospital , Zhengzhou, Henan, China.
Wen-Xia ChenDepartment of Pediatrics, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine , Zhengzhou, Henan, China.
Xiao-Li ZhangDepartment of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital , Zhengzhou, Henan, China.
Tong-Yu JiDepartment of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital , Zhengzhou, Henan, China.
Jie LiuDepartment of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital , Zhengzhou, Henan, China.
Lu RongDepartment of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital , Zhengzhou, Henan, China.
Ling-Dian WangDepartment of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital , Zhengzhou, Henan, China.
Rui-Jin ZhouDepartment of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital , Zhengzhou, Henan, China.
De-Gang DingDepartment of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital , Zhengzhou, Henan, China.
Henan Provincial People's Hospital · CNHenan University · CNZhengzhou University · CNFirst Affiliated Hospital of Henan University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microvesicles (MVs) derived from human umbilical cord mesenchymal stem cells (hUC-MSCs-MVs) and miR-21 were demonstrated to ameliorate renal ischemia-reperfusion injury (IRI). Since hUC-MSC-MVs contained a substantial quantity of miR-21, we speculated that miR-21 might account for a part of the therapeutic effects of hUC-MSCs-MVs. The human tubule epithelial (HK-2) cells were cultured under low oxygen (LO) condition to mimic a cellular IRI model. A rat model of unilateral renal IRI was established. A co-culture model of HK-2 cells and MSC-MVs was utilized to examine the therapeutic role of MSC-MVs in HK-2 cell apoptosis and mechanism. The results showed that hUC-MSCs-MVs inhibited LO-induced HK-2 cell apoptosis through transferring miR-21 to HK-2 cells. Mechanistically, miR-21 directly targeted and negatively regulated programmed cell death protein 4 (PDCD4) in HK-2 cells. Moreover, PDCD4 overexpression in HK-2 cells abrogated the hUC-MSCs-MVs-inhibited HK-2 cell apoptosis under LO condition. Additionally, the beneficial effect of MSC-MVs on rat renal IRI was partly eliminated when miR-21 was knocked down in MSCs. Taken together, MSC-MVs inhibit tubular epithelial cell apoptosis and ameliorate renal IRI, at least partially, via delivery of miR-21.

Indexed as

3' Untranslated RegionsAnimalsApoptosisApoptosis Regulatory ProteinsBase SequenceCell-Derived MicroparticlesCell LineHumansMaleMesenchymal Stem CellsMicroRNAsOxygenRats, Sprague-DawleyReperfusion InjuryRNA-Binding ProteinsUmbilical Cord3' Untranslated RegionsApoptosis Regulatory ProteinsMicroRNAsMIRN21 microRNA, humanOxygenPDCD4 protein, humanRNA-Binding ProteinsapoptosisHuman umbilical cord mesenchymal stromal cellsmicrovesiclesmiR-21PDCD4

Identifiers

PMID32329653
PMCPMC7469638
OpenAlexW3019105422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.